olivLaw · US equity research
Nautilus Biotechnology, Inc. NAUT
Laboratory Analytical Instruments · SIC 3826 · Vertical: Laboratory Analytical Instruments (SIC 3826)
Nautilus Biotechnology is developing the Nautilus Voyager platform, an integrated proteomics system that analyses single intact protein molecules to measure proteins and their proteoforms with high reproducibility. The company is still in development but recognised its first revenue in the second quarter of 2026, while it shifts resources toward proteoform applications. The proteomics research market is projected by a report cited in its filing to grow at roughly 13 percent annually to 2030, a backdrop in which the platform could gain traction if the company delivers it on schedule.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Nautilus Biotechnology, Inc. (NAUT) stock was 2.15 USD (−6.11% on the day), with market capitalisation 273.9 m USD, beta 1.78, 52-week range 0.85–3.95 USD. Latest reported quarter (Q3 2026): revenue of 234.0 k USD, net income of -15.6 m USD, diluted EPS -0.12 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 48.0
- neutral
- Bollinger (20, 2)
- 1.76 – 3.25
- in the lower half of the band · %B 0.26 · band width 59.3%
- SMA 50 / 200
- 1.70 / 2.12
- mixed trend
- MACD (12, 26, 9)
- 0.20 / 0.31
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +21.5% | −5.9% | +27.4 pp | — |
| 3 months | +142.7% | −4.6% | +147.3 pp | — |
| 6 months | −25.3% | +0.2% | −25.6 pp | — |
| Year to date | +10.3% | +7.4% | +2.8 pp | — |
| 1 year | +42.4% | +8.2% | +34.2 pp | +12.1% |
| 3 years | −12.2% | +68.4% | −80.7 pp | −4.8% |
| 5 years | −61.6% | +56.5% | −118.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | — | — | 190.0 k | 234.0 k |
| Cost of revenue | — | — | 0 | 0 | — | — | 15.0 k | 24.0 k |
| Research & development | 12.8 m | 11.5 m | 10.4 m | 9.6 m | 9.6 m | 9.7 m | 9.6 m | 10.2 m |
| SG&A | — | 7.3 m | 6.7 m | 5.9 m | — | 6.4 m | 6.3 m | 6.8 m |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -17.6 m | -16.6 m | -15.0 m | -13.6 m | -13.8 m | -14.7 m | -14.5 m | -15.6 m |
| Diluted EPS | -0.14 ≈ | -0.13 | -0.12 | -0.11 | -0.11 ≈ | -0.12 | -0.11 | -0.12 |
| Operating cash flow | -14.3 m | -13.9 m | -13.4 m ≈ | -11.0 m ≈ | -12.4 m | -13.1 m | -13.7 m ≈ | -13.3 m ≈ |
| Capex | 254.0 k | 219.0 k | 396.0 k ≈ | 418.0 k ≈ | 244.0 k | 510.0 k | 454.0 k ≈ | 1.4 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -15.6 m | -50.3 m | -57.9 m | -63.7 m | -70.8 m | -59.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.54 | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -14.9 m | -41.5 m | -48.1 m | -54.2 m | -61.3 m | -52.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 12.4 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 157.0 m USD
- Total assets
- 191.1 m USD
- Debt / equity
- unavailable
- Current ratio
- 13.33x
- ROE
- -32.3%
- ROA
- -27.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Research & development | 12.4 m | 29.4 m | 37.7 m | 47.3 m | 50.5 m | 41.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -15.6 m | -50.3 m | -57.9 m | -63.7 m | -70.8 m | -59.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -0.54 | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 29.1 m | 84.5 m | 124.6 m | 124.9 m | 125.4 m | 126.3 m | SEC (XBRL)· 26 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 36.6 m | 185.6 m | 114.5 m | 19.4 m | 27.6 m | 12.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 77.7 m | 349.2 m | 187.2 m | 176.8 m | 132.8 m | 106.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 1.4 m | 2.5 m | 3.7 m | 4.3 m | 4.1 m | 3.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 85.0 m | 398.5 m | 350.1 m | 305.6 m | 242.7 m | 191.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 470.0 k | 1.7 m | 1.3 m | 1.6 m | 987.0 k | 943.0 k | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 3.0 m | 5.8 m | 6.8 m | 9.1 m | 7.6 m | 8.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 6.3 m | 34.9 m | 35.1 m | 40.2 m | 34.0 m | 34.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | -29.7 m † | 363.6 m † | 314.9 m † | 265.4 m † | 208.7 m † | 157.0 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -14.0 m | -39.2 m | -45.8 m | -51.7 m | -59.1 m | -50.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 921.0 k | 2.3 m | 2.3 m | 2.4 m | 2.1 m | 1.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | -14.9 m ≈ | -41.5 m ≈ | -48.1 m ≈ | -54.2 m ≈ | -61.3 m ≈ | -52.0 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -25.3 m | -139.0 m | -25.7 m | -43.7 m | 66.3 m | 35.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 75.9 m | 327.4 m | 562.0 k | 368.0 k | 1.1 m | 214.0 k | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 273.9 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 9.2x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -20.1% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
NAUTILUS BIOTECHNOLOGY, INC. (NAUT). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: ROE -41.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 9.2x
What contradicts it
- FCF yield: -20.1%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Laboratory Analytical Instruments (SIC 3826) · same industry (4-digit SIC) · compared with 20 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AAgilent Technologies, Inc. | 48.4 bn | 33.9 | 21.0% | 19.5% | +6.7% | +12% / +34% |
| WATWaters Corporation | 44.5 bn | 113.0 | 1.9% | 3.6% | +7.0% | +12% / +61% |
| MTDMettler-Toledo International Inc. | 33.6 bn | 37.8 | — | 21.9% | +4.0% | +14% / +54% |
| ILMNIllumina, Inc. | 31.4 bn | 35.7 | 32.4% | 19.7% | −0.7% | +58% / +110% |
| RVTYRevvity, Inc | 16.8 bn | 71.9 | 3.2% | 8.2% | +3.7% | +44% / +70% |
| AVTRAvantor, Inc. | 10.3 bn | 30.4 | 5.9% | 5.1% | −3.4% | +29% / −29% |
| BRKRBruker Corporation | 8.8 bn | — | -5.2% | -3.5% | +2.1% | +19% / −11% |
| TXG10x Genomics, Inc. | 7.4 bn | — | -9.4% | -12.2% | +5.2% | +209% / +33% |
| PACBPacific Biosciences of California, Inc. | 760.4 m | — | — | -81.3% | +3.9% | +5% / −71% |
| CTKBCytek Biosciences, Inc. | 706.2 m | — | -23.2% | -39.1% | +0.5% | −4% / −22% |
| MASS908 Devices Inc. | 419.5 m | — | -25.2% | -57.0% | +17.7% | +60% / +28% |
| NAUTNautilus Biotechnology, Inc. | 273.9 m | — | -41.0% | — | unavailable | +42% / −12% |
| QTRXQuanterix Corporation | 130.5 m | — | -46.5% | -80.2% | +1.1% | −62% / −88% |
| SEERSeer, Inc. | 90.3 m | — | -26.4% | -478.0% | +17.0% | −15% / +1% |
| HBIOHarvard Bioscience, Inc. | 38.5 m | — | -89.9% | -11.9% | −8.1% | +11% / −80% |
| PRPOPrecipio, Inc. | 33.3 m | — | -9.0% | -4.5% | +29.8% | −24% / +172% |
| EYPTEyePoint, Inc. | 30.7 m | — | -148.7% | -10,994.7% | −27.5% | −98% / −94% |
| BNGOBionano Genomics, Inc. | 13.0 m | — | -83.6% | -106.6% | −7.4% | −41% / −99% |
| ASTCAstrotech Corporation | 8.0 m | — | -75.4% | -1,580.2% | −8.7% | +24% / −51% |
| RPIDRapid Micro Biosystems, Inc. | — | — | -141.6% | -145.6% | +19.7% | −85% / −47% |
| BIOBio-Rad Laboratories, Inc. | — | 9.7 | 14.3% | 39.5% | +0.7% | +14% / +21% |
1- and 3-year price returns: for NAUT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 28 Jul 2026; since then the company filed 8-K (27 Oct 2026 · results), 10-Q (27 Oct 2026).
In brief
Nautilus Biotechnology is developing the Nautilus Voyager platform, an integrated proteomics system that analyses single intact protein molecules to measure proteins and their proteoforms with high reproducibility. The company is still in development but recognised its first revenue in the second quarter of 2026, while it shifts resources toward proteoform applications. The proteomics research market is projected by a report cited in its filing to grow at roughly 13 percent annually to 2030, a backdrop in which the platform could gain traction if the company delivers it on schedule.
SWOT
Strengths
- The platform integrates single-molecule analysis with instruments, consumables and software, which the company describes as a differentiated approach. The leadership team has experience building businesses in the life sciences and technology industries.
- The company reports resources sufficient to fund its current operations, and the Early Access Program already provides data and customer interaction ahead of commercial launch.
- The company began generating grant and service revenue in 2026, which shows that the early access model can attract customers.
Weaknesses
- The company has not yet commercialised any product and reports net losses in every period since inception. The entire strategy depends on the success of the Voyager platform, which remains in development.
- The broadscale proteome analysis has run into performance difficulties, and the company has postponed general availability of that assay. The commercial structure is still at an early stage, with first sales hires made only in 2026.
- Commercial-scale production requires complex reagents and antibodies for which the company has not yet established supply chains.
Opportunities
- Reported demand for oncology and neurology proteoforms could open more commercial applications than the original plan. Customer requests for new targets suggest demand that could grow with the launch.
- A growing proteomics market and the need for reproducible data to train artificial intelligence models could support broader adoption if the technology is validated.
- If validation in research succeeds, the company could extend its applications into clinical diagnostics, a larger but more distant market.
Threats
- Delays in development or launch could use up resources before recurring revenue becomes significant. The company has acknowledged it will need additional capital, which could be costly or unavailable.
- Competitors with established technologies could improve performance or reduce prices, making adoption of the new platform harder.
- Economic conditions, tariffs and geopolitical conflicts could affect research budgets and the supply chains the company relies on.
Risks
- Platform not yet commercially availablehigh
Voyager is still in development and has not been launched, and if scientific or technical validation is delayed, revenue could remain minimal for an extended period.
- Need for additional capitalhigh
The company has said it will need additional funding, and if that funding is not available on acceptable terms it could be forced to reduce or delay projects.
- Delay in broadscale proteome analysismedium
The company has said the broadscale assay did not reach its target specifications for 2027, which could affect customer confidence and the commercial timeline.
- Reliance on partners for componentsmedium
The company has had difficulties with some co-development partners, and if they fail to deliver components on time the launch schedule could be affected.
- Protection of intellectual propertymedium
If patents do not provide sufficiently broad protection, competitors could develop similar products, and litigation could consume significant resources.
Investment thesis
What would need to be true (bull case)
- If the Voyager platform is launched and validated, the company could turn a large installed base of mass spectrometry instruments into a recurring sales market for instruments and consumables. The reported demand for proteoforms suggests a genuine customer interest.
- The company began generating revenue in 2026 and has resources that allow it to advance toward launch. Reallocating toward proteoforms could shorten the path to a commercial business.
- A growing proteomics market and the need for reproducible data to train artificial intelligence models could support broad adoption, and clinical applications could extend the market horizon over time.
What would break the thesis
- The company has not yet commercialised any product, and its entire strategy depends on a system that has not been validated commercially. Continuing losses could require new capital raises.
- The broadscale analysis test did not reach its target specifications, and the reallocation of resources could point to technical difficulties deeper than those disclosed publicly.
- Competitors with established technologies and large installed bases could make adoption slower than the company expects, particularly if customers prefer existing solutions.
What to watch
- Opening of pre-orders for the Voyager platformearly 2027
- General availability of the AKT1 proteoform assay within the Early Access Programlate 2026
- First Voyager instrument shipments and proteoform consumable kitsmid 2027
- Revised commercial timeline for the broadscale proteome assaynext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 28 Jul 2026; since then the company filed 8-K (27 Oct 2026 · results), 10-Q (27 Oct 2026).
The business
Nautilus Biotechnology is a development stage life sciences company seeking to quantify the complexity of the proteome through Iterative Mapping, a method that interrogates individual intact protein molecules. The Nautilus Voyager platform combines instruments, consumables and software in an integrated workflow and is designed to support both broadscale proteome analysis and targeted proteoform analysis. The company has not yet commercialised any product and had no material revenue until 2026, with a net loss of 59.0 million dollars in 2025 1.
The business model enters the market through the Iterative Mapping Early Access Program, launched in January 2026, which offers standardised analysis services before select customers buy instruments and reagents. Commercial launch of the Voyager platform is planned for early 2027 with instrument shipments from mid 2027, and the company is only now building its first sales team. If the platform is validated at scale, the company could add recurring revenue from consumables, service and software to instrument sales.
The financial profile is dominated by research and development spending, and at June 30, 2026 the company reported cash, cash equivalents and investments of 129.2 million dollars 23. The company has said its current resources fund planned operations, but it expects to need further capital as its commercial activity expands.
Segments
Early Access analysis services
The Iterative Mapping Early Access Program, launched in January 2026, provides customers with analysis and profiling performed in the company's laboratory, with data shared through a cloud platform. The first test targeted the tau protein, associated with Alzheimer's disease progression, and the company has announced an expansion to oncology proteoforms such as AKT1 with access expected in late 2026 3.
Nautilus Voyager platform
Voyager is the integrated set of instruments, consumables and software through which the company plans to sell systems to research laboratories, with pre-orders expected to open in early 2027 and instrument shipments in mid 2027 2. The company links instrument sales to recurring consumable revenue, but this has not yet been realised in any material way.
Proteoforms and broadscale proteomics
In the second quarter of 2026 the company decided to move resources away from the broadscale effort toward proteoform applications, citing market demand and performance issues with the broadscale assay. Grant revenue, including from The Michael J. Fox Foundation for alpha-synuclein proteoform development, was recognised in the period 3.
Market context
Proteomics, the study of proteins in cells and tissues, is a research market that a BCC Research report cited by the company projects to grow at roughly 13 percent annually to 2030 1. The market is served mainly by mass spectrometry and affinity-based technologies, which the company argues do not yet offer comprehensive and reproducible characterisation. The installed base of mass spectrometry proteomics instruments, which the company targets as an entry point, is estimated at over 16,000 instruments 1.
Demand from pharmaceutical companies and academic institutions depends on research and development budgets, and a reduction in those budgets could limit the company's sales. The clinical diagnostics market remains a longer-term prospect that depends on validation of the technology in translational research.
Trends
- Rising demand for reproducible proteomic datatailwind
Drug discovery teams and researchers increasingly need proteomic data that is comparable across samples, instruments and laboratories, which could favour reproducible technologies. The company links this to the need for data that can train artificial intelligence models applied to biology.
- Growing interest in proteoformsmixed
Customers have requested a growing number of proteoform targets, and the company reported strong interest in the second quarter of 2026 that led it to reallocate resources. If this demand converts into orders it could accelerate revenue, but if it does not the reallocation could become a weakness.
- Dependence on funded researchheadwind
Demand depends on research budgets of large pharmaceutical companies and academic institutions, which can be affected by economic conditions or changes in funding policy. A decline in these budgets could slow adoption of the platform.
- Supply chain and manufacturing constraintsheadwind
The platform requires hundreds of multi-affinity reagents and antibodies that are difficult to manufacture and costly to procure, and the company has not yet established sufficient internal capacity or partners. These constraints could delay the launch or raise costs.
Competitive position
The company competes with established proteomics technologies based on mass spectrometry and affinity reagents, which are already installed in laboratories and have a large base of users. The company's claimed advantage is combining breadth, proteoform depth and reproducibility in one platform, though these claims have not yet been demonstrated at commercial scale.
Competition also comes from providers of proteomics instruments and analysis services, which can offer cheaper or more familiar options to customers. The company will need to show that its platform can replace these existing methods rather than only complement them.
- Mass spectrometry proteomics suppliers
The dominant technology in the market, with a large installed base that the company targets as an entry point.
- Affinity reagent based platforms
Higher throughput approaches that the company says are limited by the availability and performance of reagents.
- Proteomics analysis service laboratories
Providers offering analysis as a service, an alternative to instrument purchase for smaller customers.
- Other emerging proteomics platforms
New technologies that could reach comparable characterisation, which the company considers incomplete today.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Give Nautilus file manager the ‘Computer’ view it lacksOMG! Ubuntu · 20 Oct 2026 · EN
- Patek Philippe a lansat un Nautilus de 285.000 CHF care nici măcar nu e ceas de mână. Noile lansări prezentate la Watches and Wonders, GenevaLibertatea.ro · 11 May 2026 · RO
The latest news item in our archive is from 20 Oct 2026; the newest SEC filing is from 27 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report27 Oct 2026
- Current report27 Oct 2026Results of operations · Financial statements and exhibits
- Current report11 Sept 2026Material agreement · Termination of a material agreement · Financial statements and exhibits
- Quarterly report28 Jul 2026
- Current report28 Jul 2026Results of operations · Financial statements and exhibits
- Current report18 Jun 2026Shareholder vote
- Proxy statement28 Apr 2026
- Quarterly report28 Apr 2026
- Current report28 Apr 2026Results of operations · Financial statements and exhibits
- Annual report26 Feb 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Nautilus Biotechnology, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Nautilus Biotechnology, Inc. · 28 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Nautilus Biotechnology, Inc. · 28 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.